However, the advent of trastuzumab and more recently several other HER2-targeting novel therapies has led to significant improvements in the prognosis, making the diagnosis a "double-edged sword." The current standard first-line therapy for patients with HER2+ metastatic breast cancer (MBC) is a ...
Fig. 1. Sources of heterogeneity in HER2-positive breast cancer. Change of tumor phenotype from primary to metastasis Since in clinical practice we base our decisions on HER2 and HR status, it is important to highlight that tumor phenotype may change from primary tumor to metastasis. A recent...
Closing out his discussion on HR+/HER2- metastatic breast cancer, Kevin Kalinsky, MD, MS, highlights key takeaways and shares excitement for future evolutions in the treatment paradigm. This is a modal window. The Playback API request failed for an unknown reason Error Code: VIDEO_CL...
EP: 1.Overview of HER2 Breast Cancer EP: 2.HER2+ Breast Cancer Diagnosis: Insights From Patients and Clinicians EP: 3.Coordinating Care for HER+ Breast Cancer Patients: A Multidisciplinary Approach EP: 4.Multidisciplinary Care of HER2+ Breast Cancer: A Patient Perspective EP: 5.Tailoring...
MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2+ breast cancer.
It is used in adult patients with unresectable or metastatic HER2-positive breast cancer who have received at least two anti-HER2-based regimens in the metastatic setting. Locally advanced or metastatic gastric cancer (b) It is used in adult patients with locally advanced or metastatic HER...
the expression and amplification of the human epidermal growth factor receptor type 2 (HER2), breast cancer can be divided into three clinical subtypes: hormone-receptor (HR)-positive (HR+; ER+, PR+/– and HER2–), HER2-positive (HER2+) and triple-negative (TN; ER–, PR– and HER2–...
Dr Sardesai on Lasofoxifene Plus Abemaciclib in ESR1-Mutant, ER+/HER2– Breast Cancer Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer ...
Despite significantadvances in the treatmentofbreast cancer, approximately30%of patients go on to develop metastatic disease and recurrence. Further, nearly20%of breast cancers arehuman epidermal growth factor receptor 2 (HER)-positive.Managementof HER2-positive metastatic and advanced disease requires car...
Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses sequencing treatments for patients with metastatic HER2-positive breast cancer. When a patient begins frontline treatment, Jhaveri recommends the use of trastuzumab (Herceptin), pertuzumab (Perjeta), and ...